One health advances最新文献

筛选

英文中文

An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant. RBD双特异性抗体有效中和严重急性呼吸系统综合征冠状病毒2型奥密克戎变异株。

One health advances Pub Date : 2023-01-01 Epub Date: 2023-04-30 DOI: 10.1186/s44280-023-00012-0

Mengqi Yuan, Yanzhi Zhu, Guanlan Liu, Yujie Wang, Guanxi Wang, Guozhong Zhang, Lilin Ye, Zhaohui Qian, Pinghuang Liu

{"title":"An RBD bispecific antibody effectively neutralizes a SARS-CoV-2 Omicron variant.","authors":"Mengqi Yuan, Yanzhi Zhu, Guanlan Liu, Yujie Wang, Guanxi Wang, Guozhong Zhang, Lilin Ye, Zhaohui Qian, Pinghuang Liu","doi":"10.1186/s44280-023-00012-0","DOIUrl":"10.1186/s44280-023-00012-0","url":null,"abstract":"Potent neutralizing antibodies (nAbs) against SARS-CoV-2 are a promising therapeutic against the ongoing COVID-19 pandemic. However, the continuous emergence of neutralizing antibody escape variants makes it challenging for antibody therapeutics based on monospecific nAbs. Here, we generated an IgG-like bispecific antibody (bsAb), Bi-Nab, based on a pair of human neutralizing antibodies targeting multiple and invariant sites of the spike receptor binding domain (RBD): 35B5 and 32C7. We demonstrated that Bi-Nab exhibited higher binding affinity to the Delta spike protein than its parental antibodies and presented an extended inhibition breadth of preventing RBD binding to angiotensin-converting enzyme 2 (ACE2), the cellular receptor of SARS-CoV-2. In addition, pseudovirus neutralization results showed that Bi-Nab improved the neutralization potency and breadth with a lower half maximum inhibitory concentration (IC50) against wild-type SARS-CoV-2, variants being monitored (VBMs) and variants of concern (VOCs). Notably, the IgG-like Bi-Nab enhanced the neutralizing activity against Omicron variants with potent capabilities for transmission and immune evasion in comparison with its parental monoclonal antibody (mAb) 32C7 and a cocktail (with the lowest IC50 values of 31.6 ng/mL against the Omicron BA.1 and 399.2 ng/mL against the Omicron BA.2), showing evidence of synergistic neutralization potency of Bi-Nab against the Omicron variants. Thus, Bi-Nab represents a feasible and effective strategy against SARS-CoV-2 variants of concern.","PeriodicalId":74344,"journal":{"name":"One health advances","volume":"1 1","pages":"12"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9901491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Introducing One Health Advances: a new journal connecting the dots for global health. 介绍One Health Advances：一本连接全球健康各点的新杂志。

One health advances Pub Date : 2023-01-01 Epub Date: 2023-03-29 DOI: 10.1186/s44280-023-00011-1

Jianzhong Shen, Stefan Schwarz

引用次数: 0

首页上一页